<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Benski AC</dc:creator>
  <dc:creator>Viviano M</dc:creator>
  <dc:creator>Jinoro J</dc:creator>
  <dc:creator>Alec M</dc:creator>
  <dc:creator>Catarino R</dc:creator>
  <dc:creator>Herniainasolo J</dc:creator>
  <dc:creator>Vassilakos P</dc:creator>
  <dc:creator>Petignat P</dc:creator>
  <dc:date>2019</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">OBJECTIVE
To assess triage compliance and the effect of the time from screening to triage on follow-up among HPV-positive women.


METHODS
We recruited 1232 women in a screening campaign in Madagascar from February to October 2015. In the first period (February-May), HPV tests were performed remotely using the cobas test. In the second period (May-October), testing was performed on-site using the Xpert HPV assay. HPV-positive women were invited for triage with visual inspection with acetic acid (VIA) and Lugol's iodine (VILI). Systematic biopsy and endocervical brushing were performed on all HPV-positive women for quality control. Three groups were defined according to time from HPV testing to triage invitation for HPV-positive women-Group I: delayed (&gt; 3 months), Group II: prompt (24-48 hours), and Group III: immediate (&lt; 24 hours).


RESULTS
A total 1232 self-sampled HPV tests were performed in the study period (496 in Group I, 512 in Group II, and 224 in Group III). Participants' mean age was 43.2 ± 9.3 years. Mean time from screening to VIA/VILI testing was 103.5 ± 43.6 days. Overall HPV prevalence was 28.0%. HPV prevalence was 27.2% in Group I (cobas test), 29.2% in Group 2 (Xpert test), and 26,7% in Group III (Xpert test). The VIA/VILI compliance rate was 77.8% for Group I, 82.7% for Group II, and 95.0% for Group III. Of women undergoing VIA/VILI, 56.3% in Group I and 43.5% in Groups II/III had positive results. Prevalence of cervical intraepithelial neoplasia grade 2 or worse among HPV-positive women was 9.8% for Group I and 6.8% for Groups II/III. Non-adherence was higher among rural women, uneducated women, and women in Group I.


CONCLUSION
HPV-positive women with immediate VIA/VILI triage invitation had the best triage compliance. A single-day test and triage strategy is preferred for low-resource settings.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/46467</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1371/journal.pone.0220632</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/31408474</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>PloS one. - 2019</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Adult</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">Biopsy</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Cervix Uteri</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Early Detection of Cancer</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Madagascar</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Papillomavirus Infections</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Patient Compliance</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Self Care</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Triage</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Uterine Cervical Neoplasms</dc:subject>
  <dc:title xmlns:ns15="xml" ns15:lang="en">HPV self-testing for primary cervical cancer screening in Madagascar: VIA/VILI triage compliance in HPV-positive women.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
